Natco Pharma Q4FY23 Results: Consolidated PAT Rose to Rs 275.8 Cr

Natco Pharma Q4FY23 Results: Consolidated PAT Rose to Rs 275.8 Cr

Natco Pharma Limited Q4 results show a revenue rise from 513.3 to 926.9 crores, an 80.58% increase in growth. EPS also rise from ₹3.41 to ₹15.11, up by 343.11%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Natco Pharma Ltd. shared its Q4 results on Monday. They earned 926.9 crores in revenue this quarter, but that’s higher than the 513.3 crores they made last quarter. The company’s growth increased by 80.58 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 275.8 crores, up from 62.3 crores in the previous quarter. Their quarter-to-quarter growth inclined by 342.70 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹15.11, which is an increase of 343.11% from the ₹3.41 EPS in the previous quarter.

Also read: ☞ ” IPCA Laboratories Q4FY23 Results: Consolidated PAT Rose to Rs 76.52 Cr “

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 2811.7 crores this year (2023), which is 37.57 percent higher than last year’s total revenue of 2043.8 crores.

This year’s PAT (Profit After Tax) is 715.3 crores, which is also 320.76% higher than last year’s PAT of 170.0 crores.

The EPS (Earnings Per Share) for this year is ₹39.18, which is 320.39% more than the EPS of ₹9.32 earned last year.

Natco Pharma Share Dividend Announcement / Record Date:

Not related to distributing a portion of a company’s earnings to shareholders in the form of cash or stock dividends. ( No Dividend Payout )

About Natco Pharma:

Natco Pharma is a multinational pharmaceutical company headquartered in Hyderabad, India. The company specializes in the manufacturing of finished dosage formulations, active pharmaceutical ingredients, and crop health science products. Additionally, it also offers contract manufacturing services.

Download the Full PDF of Q4 Results: Click Here

For more of the Latest News, Click Here

One thought on “Natco Pharma Q4FY23 Results: Consolidated PAT Rose to Rs 275.8 Cr

Leave a Reply

Your email address will not be published. Required fields are marked *